Background: Survival of patients suffering from cerebral metastases (CM) is limited. Identification of patients with a high risk for CM is warranted to adjust follow-up care and to evaluate preventive strategies.
In unselected patients with operable breast cancer, cerebral metastases (CM) occur in 3.3%-5.2% [1] . In contrast, metastatic breast cancer (MBC) patients have an elevated risk for CM affecting 10%-42% [2] [3] [4] [5] [6] . A number of risk factors for CM have been reported, e.g. early-onset breast cancer, high tumor grade, estrogen-receptor (ER)-negative, human epidermal growth factor receptor 2 (HER2)-overexpression, trastuzumab therapy and triple-negative (ER2/PR2/HER22) phenotype, HER2 overexpression and trastuzumab therapy. In addition, lung, liver and lymph nodes as first metastatic site have been reported as risk factors for subsequent CM [7] [8] [9] [10] [11] [12] [13] . Survival after occurrence of CM has been reported to be rather limited with 3-9 months median survival [8, 14] . Therefore, new approaches identifying patients with high risk for CM are urgently warranted to allow the development of preventive strategies, particularly since CM in breast cancer patients tend to increase [15] .
The aim of this explorative study was to determine diseasespecific risk factors for CM in MBC at diagnosis of first metastatic recurrence. Furthermore, we analyzed the impact of CM on survival.
methods
The data for this exploratory analysis were extracted from the prospectively running clinical tumor registry of our EUSOMA (European Society of Breast Cancer Specialists) breast cancer unit. The tumor registry data from breast cancer patients include tumor characteristics and the course of disease. Data are updated annually by the registry physician. The follow-up information is extracted either from hospital records if patients are under continuous observation in our unit or by written or telephone contact or both with the referring oncologist, physician or the patients themselves. All patients received adjuvant therapies either in clinical studies or according to current St Gallen guidelines [16] [17] [18] .
Pathomorphological tumor characteristics were documented using the current diagnostic guidelines recommended by the World Health Organization. ER and progesterone receptor (PR) were considered positive if ‡10% of the tumor cells showed expression in immunohistochemistry (IHC) using the 6F-11 antibody (ER and PR-312 antibody and PR detection; Novocastra, Berlin, Germany); HER2 was considered negative if scored as 0 or 1+by IHC (CB11 antibody; Novocastra) or if negative by fluorescence in situ hybridization test in case of an IHC score of 2+.
Four phenotypic groups of patients with respect to the receptor status of the primary tumor were assessed: ER+/PR+ or 2, HER2-negative (ER+/ HER22), ER2/PR2/HER22 (ER2/HER2), ER+/PR+ or 2, HER2-positive (ER+/HER2+) and ER2/PR-/HER2+ (ER2/PR2/HER2+).
Diagnostic workup for CM was initiated in symptomatic patients using cranial computer tomography or magnetic resonance imaging. Typical indications for imaging were unexplained headache, sensory or motoric peripheral or central neurological symptoms. Screening for CM was not carried out in asymptomatic patients. Patients with CM as first site of metastatic occurrence were excluded from these analyses because this study focused on evaluation of risk factors for secondary CM in MBC.
statistics
Descriptive statistical analysis was carried out to assess patient and disease characteristics at diagnosis of breast cancer and at first distant recurrence. Continuous data were summarized by using medians and interquartile ranges (25th and 75th percentiles), categorical data by using frequency counts and percentages.
Distant disease-free survival (DDFS) was defined as the time from the date of breast cancer diagnosis to the date of first distant metastasis. Overall survival (OS) was computed from the date of breast cancer diagnosis to the date of death from any cause. Survivors were censored at the date they were last known to be alive. Similarly, survival time subsequent to first distant metastasis, and survival time after development of CM were calculated. Survival end points were estimated with the Kaplan-Meier (KM) method. The log-rank test was used for group comparisons. KM estimates of potential follow-up were used to quantify the median follow-up time.
Occurrence of CM was the event of interest. The time to CM was measured from the time of first distant metastasis. Locoregional recurrence was not assumed to influence development of CM substantially since it does not reflect systemic disease. Thus, death before CM has been considered the only competing risk. Patients who were still alive without CM at the time of analysis were censored at the date of their last follow-up.
Cumulative incidence functions (CIFs) for CM and death without CM were constructed reflecting both events as competing risks. Comparison of cumulative incidence curves used the Gray test [19] . Fine and Gray's competing risk regression analysis [20] was applied to identify factors associated with the time to CM and death without CM. The following factors were evaluated: tumor size (T), lymph node involvement (N) and metastatic status (M) at diagnosis of breast cancer, tumor histology and grade, ER and HER2 status, DDFS, age, number of metastases at first distant recurrence and the distinct location of first metastatic site. With respect to the latter, five groups of patients were built: patients with (i) bone metastases, (ii) liver, (iii) lung, (iv) lymph node and (v) other metastases. The significance level was set to 5% (two-sided). The strength of the association between each variable and the outcome was assessed using the subhazard ratio (SHR) and the corresponding 95% confidence interval (CI). Variables associated with the event of interest (CM) at the 10% significance level on the basis of univariate analyses were included in the multivariable model. No adjustment for multiple testing was carried out. Thus, the results are not confirmatory. Statistical analyses were carried out with R version 2.10.1 and the contributed packages survcomp and cmprsk.
results
Six hundred and twenty-six patients with MBC treated between 1998 and 2008 were entered into this study. Forty-nine patients with CM were excluded from analyses before: 9 due to cerebral involvement at first diagnosis of breast cancer, 36 patients with concurrent metastases or solitary CM at first metastatic recurrence, 3 patients due to unknown site of metastatic recurrence and 1 because of concurrent ovarian cancer.
Patient characteristics at diagnosis of breast cancer and at time of first metastatic recurrence are summarized in Table 1 . Sixteen percent of patients showed HER2 overexpression and 11% triple-negative phenotype at diagnosis of breast cancer. Sixty-nine percent of all patients presented with one metastatic lesion at first distant recurrence. Bone was the first site of distant recurrence in 36% of patients. In case of overlapping metastatic sites, a 'leading metastatic site' was defined according to the highest risk of development of CM reported in the literature. Thirty-two patients had metastases in both, the lung and the liver, at diagnosis of first distant recurrence. For these patients, lung was chosen as leading metastatic site. However, we also carried out sensitivity analyses with liver as leading metastatic site without altering results.
Median follow-up time for all patients was 10.8 years from diagnosis of breast cancer, and 4.0 years from first distant metastasis, respectively. Median DDFS for all patients was 2.2 (95% CI 1.8-2.4) years. The duration of DDFS was 24 months or less in 49% of patients. Of the 626 patients included in the study, 66 patients (10.5%) developed CM. Three hundred and twenty patients (51.1%) had died before CM. There were 240 patients for whom neither CM nor death were observed.
risk factors for CM and competing risk univariate analysis. The estimates for CIF of cerebral recurrence and death without CM are presented in Figure 1A . The estimated probability that a patient with MBC will develop CM at 1 year from first distant recurrence is 5%, and this probability increases to 12% at 5 years and to 15% at 10 years from first distant recurrence, respectively. In contrast, the probability of death without CM by 1 year is 21%, and it increases to 61% at 5 years and to 76% at 10 years from first distant recurrence. Tables 2 and 3 , and Figures 1B-I present the CIF of CM and the CIF of death without CM with respect to important factors assessed at first diagnosis of breast cancer or first metastatic recurrence. Based on univariate analyses, seven variables were associated with CM: small tumor size (T1/2) at diagnosis of breast cancer (SHR = 1.90, 95% CI 1.02-3.56), primary metastatic status (M0) (SHR = 2.85, 95% CI 1.46-5.55), negative ER status (SHR = 2.37, 95% CI 1.40-4.00), positive HER2 status (SHR = 3.17, 95% CI 1.92-5.25), ductal tumor histology (SHR = 3.20, 95% CI 1.00-10.31), young age (£50 years) at first distant recurrence (SHR = 2.27, 95% CI 1.38-3.72), lung (SHR = 1.99, 95% CI 1.04-3.81) and lymph node metastases (SHR = 2.55, 95% CI 1.20-5.42) as sites of first distant recurrence. Further univariate analysis on patients with triple-negative breast cancer showed that these patients had a rather low probability to develop CM of 9% up to 13% at 1-5 years. The corresponding probability of death without CM was 44%, 67%, 70% and 81% at 1, 2, 3 and 5 years, respectively, indicating that CM are less likely to be observed in this group because they may be preceded by death without CM. Lymph node involvement (N) at first diagnosis of breast cancer was neither significantly associated with CM nor death without CM. In univariate analysis, the effect of DDFS on cerebral recurrence and death without CM was contrasting: DDFS £24 months was associated with increased risk for death without CM but not for CM after development of first distant metastases. Similar results were obtained for tumor grade. With respect to the number of different metastatic locations (1 versus >1), cerebral recurrence was probably less likely to be observed in patients with more than one distant metastasis because this event was preceded by death of these patients. multivariable analysis. In the multivariable model (Table 4) , three variables were statistically significant at the 5% level: patients presenting with primary metastatic status (M0) had a significantly higher risk to develop CM (SHR = 2.64, 95% CI 1.31-5.33) in comparison to patients with recurrent metastatic disease (M1), as well as younger patients (age £50 years) at diagnosis of metastatic recurrence (SHR = 1.97, 95% CI 1.18-3.30), and patients bearing a HER2-positive breast cancer at first diagnosis had the most elevated risk for developing CM (SHR = 2.58, 95% CI 1.52-4.39). Patients with ER-negative breast cancers had a significantly elevated probability to develop CM in the course of metastatic disease in univariate analyses ( Figure 1E ) but not in the multivariable model. Furthermore, these patients had a high competing risk burden. Patients presenting with lymph node or lung metastases had higher cumulative incidences of CM, in comparison to patients presenting with bone metastases in univariate analyses. However, this effect was not statistically significant in the multivariable model. Similarly, the impact of tumor size on development of CM was not statistically significant after adjustment for the other variables. Factors associated with the cumulative incidence of death without CM in the multivariable analysis are presented in Table 4 .
survival By the end of the observation period, 379 patients (60.5%) had died. Median OS time for all patients was 6.5 (95% CI 5.7-7.0) years. Median survival from first diagnosis of distant metastasis was 2.7 (95% CI 2.4-3.0) years for all patients. The survival curves by presence of CM are shown in Figure 2 . The median survival from first recurrence for patients with CM was 2.0 (95% CI 1.7-2.7) and 2.8 (95% CI 2.5-3.4) years for patients without CM. For the 66 patients who developed CM, median survival after cerebral recurrence was 3.5 (95% CI 2.0-6.7) months ( Figure 3) . By the end of the observation period, seven patients with CM were still alive.
CM in excluded patients
To draw a conclusive picture with respect to the appearance of CM subjected to the primary breast cancer phenotype, based on the ER and HER2 receptor status, 9 patients (20%) of the 45 excluded patients with CM as first metastatic recurrence had HER2-positive disease and 18 patients (40%) had triplenegative disease, with a median time to development of CM after first diagnosis of breast cancer of 21.9 and 23.4 months, respectively. original article
Annals of Oncology discussion
In recent years, numerous studies were published facing the problem of CM in breast cancer and it was stated that the incidence of CM was rising [8, 15] . This retrospective singleinstitution study was based on a relatively large population with 626 patients with MBC in comparison to other analyses, which were done on a smaller scale [2, 13, 21] . In our series, CM were diagnosed in 10.5% of all patients with at least one metastatic site before symptomatic cerebral involvement. Previous reports described the frequency of symptomatic CM between 5% and 16%, in asymptomatic patients even up to 42% [2] [3] [4] [5] [6] 11] . Median survival was 3.5 months in the present study, which is in line with previous reports, where survival ranged between 3 and 9 months after initial diagnosis of CM [8, 14] .
In univariate CI analysis, patients with small tumor size at diagnosis of breast cancer, primary metastatic status (M0), negative ER status, positive HER2 status, ductal tumor histology, young age (£50 years) at first distant recurrence, lung and lymph node metastases as sites of first distant recurrence were associated with higher incidences of CM. Most of these results are in line with previous reports, but to our knowledge, primary metastatic status and tumor size was not included in other reports of risk factors for CM in MBC before.
A main strength of this work is represented by the statistical approach using CI functions and adequate multivariable regression models. Slimane et al. [13] have conducted multivariate analysis in MBC and found negative ER status and lung metastases as independent risk factors for CM, but the statistical methodology by using a Cox regression model was not appropriate in this setting. The competing risk of death in MBC is not reflected adequately in these models since patients who are dead are no longer at risk for CM, although it is assumed hazard ratios for CM are overrated [22] . Nevertheless, there is biological evidence for lung metastases to be a risk factor for CM and patients suffering from lung metastases tend to show CM more frequently. Breast cancer cells show an organotropism, driven by chemokine-mediated movement to specific organs. The chemokine receptor CXCR4 is expressed in most breast cancer cells [23] . SDF-1a (stromal cell-derived factor-1a), the exclusive ligand for CXCR4, is expressed in the lung and brain [24] . Breast cancer cells that express CXCR4 are attracted by tissues expressing high levels of SDF-1a, which causes breast cancer cells to leave the circulation and to proliferate and to induce angiogenesis and metastases [23] . In gene expression analyses of breast cancer cells, prone to metastasize to the brain, it was recently shown that these cells have specific gene expression patterns. The expression of cyclooxygenase-2 and heparin-binding epidermal growth factor in primary tumors enhanced cancer cells for extravasation through the nonfenestrated capillaries of the brain and lungs, mainly, whereas a2,6-sialyltransferase expression was the most specific mediator of cancer cell infiltration through the bloodbrain barrier. Thus, it was stated that cell surface sialylation may be an important mechanism in the development of brain metastasis and a potential therapeutical target [25] .
It was confirmed in the present study that the CI of patients developing CM was higher in the group of patients with lung metastases, but this was not true in the multivariable model. Lymph node metastases are most common in patients with MBC, but even an association to CM has been reported before [4, 9, 26] , although there were no statistically significant associations in the multivariable model in our study.
In multivariable regression analysis of CI, risk factors for CM that were previously reported in advanced breast cancer were confirmed: HER2-positive tumors assessed in diagnostic workup at first diagnosis of breast cancer and younger age at first metastatic recurrence [2-6, 9, 27] . The matter of HER2 overexpression as risk factor for CM is a case of distinct discussion and controversy results have been presented over the last decade. Some authors found HER2-positive tumors as risk factors for CM in retrospective [28, 29] studies, even with no trastuzumab treatment, e.g. raising CI from 3.5% to 6.8% (P < 0.0001) in HER2-negative and HER2-positve tumors, respectively. In comparison, Dawood et al. [30] demonstrated that patients with HER2-positive disease who did not received trastuzumab in first-line therapy showed shorter time to development of CM in comparison to patients treated with trastuzumab, 2.1 versus 13.1 months, respectively.
It was not the purpose of the present work to determine therapy-related factors influencing the development of CM; numerous other works have dealt with this problem before [2, 26, [31] [32] [33] , but nearly all HER2-positive patients will have received first-line trastuzumab therapy, guideline adapted. Nevertheless, it is most likely that trastuzumab therapy influenced the development of CM. Patients with HER2-positive tumors showed a reduced CI of death compared with HER2-negative patients ( Figure 1H ), although the aggressive nature of HER2-positive tumors would suggest a worse course of the disease in comparison to HER2-negative tumors, indicating an active role of trastuzumab therapy. The reason for HER2-positve patients to bear the highest risk for CM might be most likely due to longer survival caused by control of visceral disease and a longer time for metastatic cells to seed in the cerebrum without getting eradicated by trastuzumab, not crossing the intact blood-brain barrier adequately [15] .
Patients suffering from secondary metastatic disease were significantly more likely to develop CM than patients presenting with primary metastatic disease (M1) in multivariable analyses. At least two explanations might explain this phenomenon: (i) patients receiving adjuvant chemotherapy survive as long to experience the development of CM, in contrast to patients with primary systemic disease, who will die rather quickly from systemic disease (proposing that all metastatic spread takes place at an early stage of the disease) [33] ; (ii) patients with primary systemic disease were not exposed to chemotherapeutics before, thus malignant cells are rather susceptible to cytotoxic therapy in comparison to patients, who will have received adjuvant chemotherapy.
Clustering analyses included the triple-negative breast cancer phenotype, the clinical surrogate for the genotypic basal-like phenotype, which is routinely assessed during histopathological workup [34] . Triple-negative breast cancer was not a striking risk factor for CM in our study, although it has been reported before [6, 35] . The most important reason for this observation seems to be the high risk of early recurrence in these patients. Of the 45 patients excluded to the present study due to earlier occurrence of CM, 40% showed triple-negative receptor status, 20% of all patients with triple-negative receptor status with metastatic disease. This is in line with previous reports indicating an earlier recurrence of triple-negative breast cancer patients [36] and a high prevalence of CM as first site of metastatic occurrence in this subset of patients [35] . Moreover, CI of the competing risk in triple-negative patients was tremendous, indicating an aggressive course of the disease, thus minimizing the risk to develop CM due to death. This was in part also true for a negative ER status, being associated with higher CI of CM in univariate analysis, like reported several times before [9, 13, 27] , but it was not confirmed as an independent risk factor, exhibiting a high competing risk burden, additionally.
There is significant disagreement between clinical researchers if CM are a life-limiting diagnosis. In an explorative analysis, Miller et al. did not find any survival benefit between patients with occult versus symptomatic CM if each patient was treated at first diagnosis with whole brain radiation therapy (WBRT). They concluded that CM appeared to be an indicator for, rather than a cause of, limited survival [12] . Others recommended prophylactic treatment strategies in patients with high risk for CM [2, 26, 31, 32] , at least implying this entity to be life limiting. We showed that patients who develop CM in the course of metastatic disease had an impaired survival, although the competing risks, mainly in patients with independently higher risks for CM, were less pronounced. This indicates that CM are a putative life-limiting event, which is in line with at least one previous report [12] . However, there are no prospective data confirming the hypothesis that preventive strategies would have the capacity to reduce the number of CM in breast cancer patients and it remains speculative if patients would benefit in terms of longer survival. The first step to further elucidate this potential strategy is to identify patients with a high risk. These patients could then be offered participation in thoroughly designed prevention trials. WBRT is the main option to prevent CM in adjuvant treatment of small-cell lung cancer, reducing the cumulative incidence of CM and leading to an OS benefit [37] . However, this strategy could not be translated into treatment of breast cancer: in contrast to lung cancer, most patients receiving adjuvant therapy will not die because of breast cancer and many patients would be treated for no benefit but with potential serious side-effects. Therefore, preventive strategies might be limited to patients with metastatic disease. In order to evaluate this strategy, at least two trials have been launched in locally advanced or MBC [38, 39] . These trials are limited to patients with HER2-positive tumors but do not include further risk factors, hence it is most likely that a substantial proportion of patients not developing CM in their course of disease will receive WBRT unfounded. Another option possibly leading to a prevention of CM in HER2 positive was recently unfolded. A multicenter phase II trial included patients with HER2-positve progressive CM and these patients were treated with lapatinib, a dual tyrosinkinase inhibitor. It was demonstrated that there was a modest activity, reducing the volume of the metastases. In continuation of these results, a phase III trial (CNS as First Site of Relapse on Lapatinib or Trastuzumab Evaluation Trial) was initiated, examining the efficacy of lapatinib in MBC to prevent CM.
Limitations of the present study are the retrospective and single-institution character possibly leading to selection and referral bias and the limited number of patients included to this study.
conclusions
In a cohort of patients with MBC, independent disease-specific risk factors for CM were HER2-positive tumors at first diagnosis of breast cancer, younger age and secondary metastatic disease, rather than primary MBC. Although the competing risk of death is a strong confounder with respect to the development of CM in MBC, patients with identified risk factors for CM tend to be less affected by these events.
Survival of patients with symptomatic CM in the course of MBC is shortened in comparison to patients not developing this deleterious metastatic site.
